Welcome to our dedicated page for PACIFIC BIOSCIENCES OF CALIFORNIA SEC filings (Ticker: PACB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PACIFIC BIOSCIENCES OF CALIFORNIA's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PACIFIC BIOSCIENCES OF CALIFORNIA's regulatory disclosures and financial reporting.
Pacific Biosciences of California, Inc. reported that it announced financial results for its third fiscal quarter ended September 30, 2025. The company disclosed that these third-quarter 2025 results, covering its results of operations and financial condition, are presented in a press release titled “PacBio Announces Third Quarter 2025 Financial Results.”
The press release is furnished as Exhibit 99.1 to this report, meaning it provides the detailed quarterly figures and commentary, while the report itself primarily serves to formally notify investors that the results have been released.
Mark Van Oene, Chief Operating Officer of Pacific Biosciences of California, Inc. (PACB), reported a routine sale of shares to cover tax withholding upon RSU vesting. The Form 4 discloses that on 08/18/2025 he disposed of 26,836 shares at a weighted average sale price of $1.311 per share (sale prices ranged from $1.30 to $1.32). After the transaction he beneficially owns 1,920,035 shares. The filing explains the shares were automatically sold to satisfy tax withholding obligations related to restricted stock unit vesting. The Form 4 was signed by an attorney-in-fact on 08/20/2025.
Pacific Biosciences (PACB) filed a Form 144 reporting a proposed sale of 26,836 restricted common shares acquired on 08/15/2025. The filing lists the broker as Morgan Stanley Smith Barney LLC and shows an aggregate market value of $35,173.95 with an approximate sale date of 08/18/2025 on NASDAQ. The issuer's total shares outstanding are reported as 300,370,611. The filer indicates there were no securities sold in the past three months for the same account and signs the standard representation that they are not aware of undisclosed material adverse information.
Multiple related parties reported material holdings in Pacific Biosciences (PACB). Madrone Opportunity Fund directly holds 16,762,216 shares (5.6% of class) and Shimoda Holdings directly holds 3,500,000 shares (1.2%). Gregory Boyd Penner is reported as an individual with aggregate beneficial ownership of 20,262,216 shares (6.8% of class), reflecting his roles across the filing entities.
The filing discloses that the reported shares carry shared voting and shared dispositive power among the reporting persons and that the percentage figures are calculated using 300,084,685 shares outstanding as the denominator. The reporting persons expressly disclaim status as a "group."
Edmond de Rothschild Asset Management (France & Luxembourg) and Edmond de Rothschild Fund submitted Amendment No. 1 to Schedule 13G for Pacific Biosciences of California, Inc. (PACB), triggered by the 30 Jun 2025 measurement date.
- Aggregate shares: 13.37 million (EDRAM France) and 12.08 million (each Luxembourg entity).
- Ownership: 4.5 % of outstanding common stock for EDRAM France; 4.0 % for EDRAM Luxembourg and EdR Fund—placing all filers below the 5 % reporting threshold.
- Voting/Dispositive power: Shared voting & dispositive authority over 12.08 million shares; sole dispositive power limited to 1.28 million shares; no sole voting power.
- The filers certify the stake is held in the ordinary course of business as passive investment managers, with no intent to influence control.
The filing confirms continued, but sub-5 %, institutional support from a prominent European asset manager without signaling activist involvement.